Gabapentin vs Pregabalin

Pregabalin demonstrates more predictable and linear pharmacokinetics compared to gabapentin. Gabapentin's absorption is dose-dependent and saturable — bioavailability decreases from approximately 60% at 300 mg to 33% at 1600 mg — because it relies on a transport system (LAT1) in the small intestine that becomes saturated at higher doses. Pregabalin has consistent bioavailability of approximately 90% regardless of dose.

For postherpetic neuralgia, both medications have demonstrated efficacy in randomized controlled trials. Pregabalin at 300-600 mg/day showed significant pain reduction in the pivotal registration trials. Gabapentin at 1800-3600 mg/day showed comparable efficacy. No head-to-head superiority trial exists comparing the two directly for this indication.

For diabetic peripheral neuropathy, pregabalin is FDA-approved based on trials showing significant pain reduction at 300-600 mg/day. Gabapentin has strong supporting evidence at doses of 1800-3600 mg/day, though its official FDA indication is for postherpetic neuralgia only.

For fibromyalgia, pregabalin is the only gabapentinoid with FDA approval, based on trials demonstrating significant improvement in pain, sleep quality, and fatigue at 300-450 mg/day. Gabapentin has been studied in smaller trials for fibromyalgia with positive results, but lacks FDA approval for this indication.

Pregabalin's faster onset of therapeutic effect (within the first week) compared to gabapentin (which may take 2-3 weeks at adequate doses) is attributed to its superior bioavailability and more predictable dose-response.

Both gabapentinoids share a similar side effect profile, with the most common effects being dizziness ^[1][2], somnolence ^[1][2], peripheral edema, and weight gain ^[1][2]. These effects are dose-dependent and often diminish with continued use.

Dizziness occurs in approximately 20-30% of pregabalin users and 15-20% of gabapentin users. Somnolence affects approximately 15-25% and 15-20%, respectively. Peripheral edema (swelling, particularly in the legs) occurs in 5-16% of pregabalin users and 2-8% of gabapentin users.

Weight gain is a concern with both medications, affecting approximately 10-15% of patients. The mechanism involves increased appetite and possibly fluid retention. Average weight gain ^[1][2] ranges from 2-5 kg over 6-12 months of treatment.

Pregabalin is classified as a Schedule V controlled substance by the DEA due to reports of euphoria and misuse potential. Gabapentin is not federally scheduled, though several US states have added gabapentin to their controlled substance schedules due to increasing reports of misuse. Both can cause withdrawal symptoms if discontinued abruptly.

Visual disturbances (blurred vision) are reported more frequently with pregabalin. Cognitive effects (difficulty concentrating, "brain fog") can occur with both medications. Respiratory depression risk exists when either is combined with opioids, prompting FDA warnings.

Cost is one of the most significant differences between these medications. Generic gabapentin ^[1] is very inexpensive, typically costing $4-$15 per month for commonly prescribed doses. It is one of the most affordable medications on the market.

Generic pregabalin ^[2] became available in 2019, significantly reducing its cost from the previous brand-only price of over $400 per month. Generic pregabalin ^[2] now costs approximately $15-$50 per month, still substantially more expensive than gabapentin.

Both medications are covered by most insurance plans, though some insurers may require step therapy (trying gabapentin first) before covering pregabalin. This step-therapy approach is common given the cost difference and similar efficacy profiles.

Dosing convenience differs between the two medications. Gabapentin is typically dosed three times daily (TID) due to its shorter half-life, which can impact medication adherence. Extended-release formulations (Gralise, Horizant) allow once-daily dosing but are brand-name only and more expensive.

Pregabalin is dosed twice daily (BID) or three times daily depending on the indication, offering slightly better convenience. Its predictable dose-response means dose titration is more straightforward.

Neither medication requires routine blood monitoring. Both should be dose-adjusted in patients with kidney impairment. Both can be taken with or without food, though gabapentin absorption may be slightly improved with food.

For most patients, gabapentin is a reasonable first choice given its substantially lower cost, extensive safety track record, and similar efficacy for most indications. Many insurance plans and treatment guidelines recommend gabapentin as a first-line gabapentinoid.

Pregabalin may be preferred when gabapentin has been tried and failed to provide adequate relief at maximum tolerated doses, when predictable dosing and faster onset are important, for FDA-approved fibromyalgia treatment, or when twice-daily (rather than three-times daily) dosing would improve adherence.

Patients with a history of substance use disorder should be counseled about the abuse potential of both medications, with pregabalin carrying a higher risk profile (Schedule V). Both should be tapered rather than stopped abruptly to avoid withdrawal symptoms.

For elderly patients, starting at low doses and titrating slowly is important with both medications due to the risk of dizziness and falls. Kidney function should guide dose adjustments in both cases. Consult your healthcare provider to determine which option best fits your clinical needs.